I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Susan Mahony Biography and Net Worth

SVP of Eli Lilly and Company

Dr. Susan Mahony joined the board in August 2019. Dr. Mahony serves on the boards of directors of Zymeworks Inc., a public biopharma company; Vifor Pharma AG, a public pharmaceutical company; Assembly Biosciences Inc., a public biotechnology company; Cereius Inc., a private biotechnology company and Altis Biosystems, a private biotechnology company. Previously, Dr. Mahony served as senior vice president and president of Lilly Oncology and was a member of the executive committee at Eli Lilly and Company from 2009 until her retirement in August 2018. Before that, Dr. Mahony served in a variety of leadership roles at Eli Lilly and Company, including senior vice president, human resources and diversity; president and general manager, Lilly Canada; and executive director, global brand development. Dr. Mahony worked in sales and marketing at Bristol-Myers Squibb Company from 1995 to 2000, at Amgen Limited from 1991 to 1995 and at Schering Plough from 1989 to 1991. Dr. Mahony also serves on the board of Chordoma Foundation, a nonprofit organization dedicated to improving the lives of those affected by chordoma.

Dr. Mahony earned a Bachelor of Science and Doctorate of Philosophy (Ph.D.) in pharmacy, as well as a Master of Business Administration from London Business School. She was awarded an honorary doctorate from Aston University.

What is Susan Mahony's net worth?: The estimated net worth of Susan Mahony is at least $34.92 million as of April 13th, 2018. Dr. Mahony owns 45,652 shares of Eli Lilly and Company stock worth more than $34,919,215 as of December 18th. This net worth estimate does not reflect any other investments that Dr. Mahony may own. Learn More about Susan Mahony's net worth.
How do I contact Susan Mahony?: The corporate mailing address for Dr. Mahony and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Susan Mahony's contact information.
Has Susan Mahony been buying or selling shares of Eli Lilly and Company?: Susan Mahony has not been actively trading shares of Eli Lilly and Company during the last ninety days. Most recently, Susan Mahony sold 22,544 shares of the business's stock in a transaction on Monday, April 16th. The shares were sold at an average price of $80.09, for a transaction totalling $1,805,548.96. Following the completion of the sale, the senior vice president now directly owns 45,652 shares of the company's stock, valued at $3,656,268.68. Learn More on Susan Mahony's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 11/8/2024.

Susan Mahony Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2018	Sell	22,544	$80.09	$1,805,548.96	45,652
4/13/2018	Sell	5,165	$80.14	$413,923.10	45,652
12/4/2017	Sell	36,585	$86.18	$3,152,895.30	54,885
12/16/2016	Sell	20,242	$72.65	$1,470,581.30	67,802
7/28/2014	Sell	2,065	$63.30	$130,714.50
7/25/2014	Sell	30,000	$63.90	$1,917,000.00
3/26/2013	Sell	5,000	$56.00	$280,000.00

Susan Mahony Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $764.71

$762.50

$779.00

50 Day Range

MA: $828.39

$727.57

$932.06

2 Week Range

Now: $764.71

$567.02

$972.53

Volume

3,194,057 shs

Average Volume

3,209,158 shs

Market Capitalization

$725.95 billion

P/E Ratio

82.67

Dividend Yield

0.66%

Beta

0.41

I was wrong. Dead wrong.

From Porter & Company | Ad